Showing results (1-10 of 61) with videos related to
Sort By:
Pageof 7
Therapeutic Drug Monitoring|August 1, 1996
Clinical development of a cyclosporine microemulsion in transplantationJ M Kovarik, E A Mueller, D NieseAntimicrobial Agents and Chemotherapy|May 1, 1989
Influence of fluoroquinolones on expression and function of P fimbriae in uropathogenic Escherichia coliJ M Kovarik, I M Hoepelman, J VerhoefEuropean Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|September 1, 1989
Once-daily aminoglycoside administration: new strategies for an old drugJ M Kovarik, I M Hoepelman, J VerhoefJournal of Clinical Pharmacology|July 7, 2000
Product equivalence study comparing the tolerability, pharmacokinetics, and pharmacodynamics of various human immunoglobulin-G formulationsI Andresen, J M Kovarik, M Spycher, et al.Journal of Clinical Pharmacology|March 20, 1998
Optimizing the absorption of valspodar, a P-glycoprotein modulator, Part II: Quantifying its pharmacokinetic variability and refining the bioavailability estimateJ M Kovarik, E A Mueller, F Richard, et al.The British Journal of Dermatology|February 1, 1992
Dose-proportional pharmacokinetics of terbinafine and its N-demethylated metabolite in healthy volunteersJ M Kovarik, S Kirkesseli, H Humbert, et al.Transplantation Proceedings|December 19, 2006
Exposure-efficacy relationships of a fingolimod-everolimus regimen in kidney transplant patients at risk for delayed graft functionJ M Kovarik, H Tedesco-Silva, M I Lorber, et al.Transplant International : Official Journal of the European Society for Organ Transplantation|January 1, 1996
Predicting patients' exposure to cyclosporinA Johnston, J M Kovarik, E A Mueller, et al.Clinical Pharmacology and Therapeutics|November 5, 1999
Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxinJ M Kovarik, L Rigaudy, M Guerret, et al.Pageof 7